治疗肺部疾病的中药活性成分可吸入纳米给药系统研究进展

程方瑞; 孙爽; 张欢; 李永吉; 吕邵娃

doi:10.6039/j.issn.1001-0408.2024.23.19

您当前的位置：

首页 >

文章列表页 >

治疗肺部疾病的中药活性成分可吸入纳米给药系统研究进展

综述 | 更新时间：2024-12-09

- 治疗肺部疾病的中药活性成分可吸入纳米给药系统研究进展
- Research progress on inhalation nano-drug delivery systems of active ingredients of traditional Chinese medicine for pulmonary diseases
- 中国药房 2024年35卷第23期页码：2954-2958
- 作者机构：
  
  黑龙江中医药大学药学院/教育部北药基础与应用研究重点实验室，哈尔滨　150040
- 作者简介：
  
  硕士研究生。研究方向：新药研究与开发。E-mail：2108170706@qq.com
  教授，硕士生导师。研究方向：新药研究与开发。电话：0451-87266916。E-mail：lswa5599@hotmail.com
- 基金信息：
  
  黑龙江省“头雁”计划（No.〔2019〕5号）;黑龙江省博士后科研启动金项目(LBH-Q21189)
- DOI：10.6039/j.issn.1001-0408.2024.23.19
  中图分类号： R944
- 纸质出版日期：2024-12-15，
  
  收稿日期：2024-06-16，
  
  修回日期：2024-10-09，
- 稿件说明：
移动端阅览
程方瑞,孙爽,张欢等.治疗肺部疾病的中药活性成分可吸入纳米给药系统研究进展 ^Δ[J].中国药房,2024,35(23):2954-2958.

CHENG Fangrui,SUN Shuang,ZHANG Huan,et al.Research progress on inhalation nano-drug delivery systems of active ingredients of traditional Chinese medicine for pulmonary diseases[J].ZHONGGUO YAOFANG,2024,35(23):2954-2958.
程方瑞,孙爽,张欢等.治疗肺部疾病的中药活性成分可吸入纳米给药系统研究进展 ^Δ[J].中国药房,2024,35(23):2954-2958. DOI： 10.6039/j.issn.1001-0408.2024.23.19.

CHENG Fangrui,SUN Shuang,ZHANG Huan,et al.Research progress on inhalation nano-drug delivery systems of active ingredients of traditional Chinese medicine for pulmonary diseases[J].ZHONGGUO YAOFANG,2024,35(23):2954-2958. DOI： 10.6039/j.issn.1001-0408.2024.23.19.

摘要

肺部给药能直接将药物运送至肺部，是肺部疾病的优选给药方式。中药活性成分如槲皮素、紫杉醇等对肺部疾病具有良好的治疗效果，但其存在水溶性差和肺清除率高等问题。将中药活性成分负载在纳米给药系统中，可提高药物的水溶性、稳定性及其在肺部的渗透性和滞留性。基于此，本研究综述了治疗肺部疾病的中药活性成分可吸入纳米给药系统的研究进展，发现有基于壳聚糖、脂质（包括脂质体、固体脂质纳米粒、纳米结构脂质载体）、靶向配体（包括靶向叶酸受体、靶向转铁蛋白受体、外泌体）的中药活性成分可吸入纳米给药系统，这些纳米给药系统综合考虑了粒径、表面电荷和疏水性等关键因素，可避免药物被黏液、纤毛和巨噬细胞清除，具有较好的应用潜力。

Abstract

Pulmonary administration can directly deliver drugs to the lungs， making it the preferred mode of administration for pulmonary disease. Active ingredients of traditional Chinese medicine （TCM）， such as quercetin and paclitaxel have demonstrated promising therapeutic effects on lung diseases. However， they face challenges such as poor water solubility and high lung clearance rates. Loading the active ingredients of TCM onto nano-drug delivery systems can enhance their water solubility， stability， permeability and retention in the lungs. Based on this， this study reviewed the research progress on inhalation nano-drug delivery systems for the active ingredients of TCM in the treatment of lung diseases. It was found that there are nano-drug delivery systems for TCM active ingredients based on chitosan， lipids （including liposomes， solid lipid nanoparticles， and nanostructured lipid carriers）， and targeting ligands （including targeting folate receptor， targeting transferrin receptor， and exosomes）. These inhalation nano-drug delivery systems comprehensively consider key factors such as particle size， surface charge， and hydrophobicity， which can prevent the drugs from being cleared by mucus， cilium and macrophages， thus exhibiting great potential for application.

关键词

可吸入纳米给药系统中药活性成分肺部疾病

Keywords

active ingredients of traditional Chinese medicinepulmonary diseases

references

GUO X P，ZUO X，ZHOU Z J，et al. PLGA-based micro/nanoparticles：an overview of their applications in respiratory diseases[J]. Int J Mol Sci，2023，24（5）：4333.

YAO J J，LI Y X，MENG F，et al. Enhancement of suppression oxidative stress and inflammation of quercetin by nano-decoration for ameliorating silica-induced pulmonary fibrosis[J]. Environ Toxicol，2023，38（7）：1494-1508.

KAUR P，GARG T，RATH G，et al. Development，optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design[J]. Drug Deliv，2016，23（6）：1912-1925.

MIN S H，LEI W，JUN C J，et al. Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy[J]. Expert Opin Investig Drugs，2023，32（8）：723-739.

SHEN A M，MINKO T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery[J]. J Control Release，2020，326：222-244.

YUE P F，ZHOU W C，HUANG G T，et al. Nanocrystals based pulmonary inhalation delivery system：advance and challenge[J]. Drug Deliv，2022，29（1）：637-651.

YONG J Y，SHU H L，ZHANG X，et al. Natural products-based inhaled formulations for treating pulmonary diseases[J]. Int J Nanomedicine，2024，19：1723-1748.

GUAGLIARDO R，PÉREZ-GIL J，DE SMEDT S，et al. Pulmonary surfactant and drug delivery：focusing on the role of surfactant proteins[J]. J Control Release，2018，291：116-126.

GARCÍA-FERNÁNDEZ A，SANCENÓN F，MARTÍNEZ- MÁÑEZ R. Mesoporous silica nanoparticles for pulmonary drug delivery[J]. Adv Drug Deliv Rev，2021，177：113953.

FENG X J，SHI Y，ZHANG Y，et al. Opportunities and challenges for inhalable nanomedicine formulations in respiratory diseases：a review[J]. Int J Nanomedicine，2024，19：1509-1538.

DENG Y D，ZHANG X D，SHEN H B，et al. Application of the nano-drug delivery system in treatment of cardiovascular diseases[J]. Front Bioeng Biotechnol，2019，7：489.

MIKUŠOVÁ V，MIKUŠ P. Advances in chitosan-based nanoparticles for drug delivery[J]. Int J Mol Sci，2021，22（17）：9652.

LEONG E W X，GE R W. Lipid nanoparticles as delivery vehicles for inhaled therapeutics[J]. Biomedicines，2022，10（9）：2179.

ANDERSON S，ATKINS P，BÄCKMAN P，et al. Inhaled medicines：past，present，and future[J]. Pharmacol Rev，2022，74（1）：48-118.

NSAIRAT H，KHATER D，SAYED U，et al. Liposomes：structure，composition，types，and clinical applications[J]. Heliyon，2022，8（5）：e09394.

ZHANG T T，CHEN Y M，GE Y Y，et al. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers[J]. Acta Pharm Sin B，2018，8（3）：440-448.

PALIWAL R，PALIWAL S R，KENWAT R，et al. Solid lipid nanoparticles：a review on recent perspectives and patents[J]. Expert Opin Ther Pat，2020，30（3）：179-194.

ABDULBAQI I M，ASSI R A，YAGHMUR A，et al. Pulmonary delivery of anticancer drugs via lipid-based nanocarriers for the treatment of lung cancer：an update[J]. Pharmaceuticals，2021，14（8）：725.

YANG Y，HUANG Z W，LI J Y，et al. PLGA porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel：novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer[J]. Adv Healthc Mater，2019，8（23）：e1900965.

VIEIRA I R S，CONTE-JUNIOR C A. Nano-delivery systems for food bioactive compounds in cancer：prevention，therapy，and clinical applications[J]. Crit Rev Food Sci Nutr，2024，64（2）：381-406.

GADAG S，NARAYAN R，NAYAK A S，et al. Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for locali- zed delivery to breast cancer therapy[J]. Int J Pharm，2021，606：120877.

RIZWANULLAH M，AHMAD M Z，GARG A，et al. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application[J]. Biochim Biophys Acta Gen Subj，2021，1865（9）：129936.

GONZALEZ T，MUMINOVIC M，NANO O，et al. Folate receptor alpha：a novel approach to cancer therapy[J]. Int J Mol Sci，2024，25（2）：1046.

ROSIÈRE R，VAN WOENSEL M，GELBCKE M，et al. New folate-grafted chitosan derivative to improve deli- very of paclitaxel-loaded solid lipid nanoparticles for lung tumor therapy by inhalation[J]. Mol Pharm，2018，15（3）：899-910.

ZHU X J，KONG Y，LIU Q，et al. Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy[J]. Pulm Pharmacol Ther，2019，55：50-61.

HAN L，HUANG R Q，LIU S H，et al. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors[J]. Mol Pharm，2010，7（6）：2156-2165.

ABDELAZIZ H M，ELZOGHBY A O，HELMY M W， et al. Inhalable lactoferrin/chondroitin-functionalized monoolein nanocomposites for localized lung cancer targeting[J]. ACS Biomater Sci Eng，2020，6（2）：1030-1042.

ZHANG X W，SHAN M R，LI S Y，et al. Investigating the trans-membrane transport of HAIYPRH peptide-decorated nano-drugs[J]. Phys Chem Chem Phys，2023，25（14）：9766-9771.

RIAZ M K，ZHANG X，WONG K H，et al. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy[J]. Int J Nanomedicine，2019，14：2879-2902.

ROSHANCHESHM S，ASADI A，KHOSHNAZAR S M，et al. Application of natural and modified exosomes a drug delivery system[J]. Nanomed J，2022，9（3）：192-204.

ZHENG W，ZHU T C，TANG L T，et al. Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer[J]. J Transl Med，2023，21（1）：383.

BARJAKTAREVIC I Z，MILSTONE A P. Nebulized therapies in COPD：past，present，and the future[J]. Int J Chron Obstruct Pulmon Dis，2020，15：1665-1677.

YAMAMOTO H，KUNO Y，SUGIMOTO S，et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions[J]. J Control Release，2005，102（2）：373-381.

MILLER M R，RAFTIS J B，LANGRISH J P，et al. Inhaled nanoparticles accumulate at sites of vascular disease[J]. ACS Nano，2017，11（5）：4542-4552.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据